6550--Intent to Sole Source: Cepheid GeneXpert Infinity Molecular Reagents IDIQ
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The Department of Veterans Affairs (VA), specifically the Network Contract Office 8, is seeking responses for a Single Award Indefinite Delivery Indefinite Quantity (IDIQ) contract for Cepheid GeneXpert Infinity Molecular Reagents. While initially an intent to sole source with Cepheid, this notice serves as a solicitation to determine if competitive procurement is feasible. Offers are due by February 20, 2026, at 13:00 EST.
Opportunity Overview
This procurement aims to secure an extensive range of infectious disease testing reagents for use on existing Cepheid GeneXpert Infinity instruments at the Bay Pines VA Healthcare System. The VA's initial intent was to award a sole source contract to Cepheid, citing their unique capability to meet the agency's needs. However, this solicitation is being issued to allow other responsible sources to demonstrate their interest and capability to provide the required reagents, potentially leading to a competitive procurement.
Scope of Work
The contract requires the procurement and delivery of specific FDA-approved Cepheid GeneXpert® Infinity compatible reagents for PCR testing of infectious disease agents. These include reagents for:
- Methicillin Resistant Staph aureus (MRSA)
- Clostridioides (Clostridium) difficile Toxin (C diff)
- Carbapenemase Resistant Enterobacteriaceae (CRE)
- Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG)
- Beta hemolytic Streptococcus Group A (Streptococcus pyogenes)
- SARS-CoV-2, Hemophilus influenzae (influenza A and influenza B), Respiratory syncytial virus (RSV)
- Vaginal Infection Molecular Test
The vendor must support automatic shipments on standing orders or monthly, as well as "As Needed" or "Emergent Overnight" capabilities, covering all shipping costs. Information regarding hazardous constituents for local discharge requirements must also be provided.
Contract Details
- Contract Type: Single Award Indefinite Delivery Indefinite Quantity (IDIQ), Fixed-Priced.
- Period of Performance: Ordering periods from April 1, 2026, through September 30, 2029.
- Guaranteed Minimum Award: $100,000.00.
- Maximum Aggregate Value: $3,500,000.00.
- Set-Aside: None (Unrestricted).
- NAICS Code: 325413 (In-Vitro Diagnostic Substance Manufacturing), Size Standard: 1250 Employees.
- Place of Performance: Bay Pines VA Healthcare System, Bay Pines, Florida.
Submission & Evaluation
This is not a request for competitive proposals in the traditional sense, but rather an inquiry to determine if a competitive procurement is feasible. The government intends to evaluate offers and award without discussions. Interested parties must submit a quotation, bid, or proposal demonstrating their ability to comply with the requirement. If no responses are received, the government will proceed with the sole source acquisition.
Response Deadline
Responses must be emailed to Moneque Rodriguez (moneque.rodriguez@va.gov) by February 20, 2026, at 13:00 PM Eastern Standard Time.